Arcellx

Arcellx Short-term Debt

Delisted

The Short-Term Debt of Arcellx (ACLX) as of Nov 21, 2026 is 7.58 M USD. In the previous year, Short-Term Debt was 7.54 M USD — a change of 0.56% (higher).

Short-term Debt

7.58 MUSD

YoY

0.56%

Last updated:

Short-Term Debt of Arcellx is 2025 7.58 M USD. Short-Term Debt of Arcellx was 2024 7.54 M USD. It decreases by 0.56% higher compared to the previous year.

The Arcellx Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2021
100,000.00 USD
Jan 1, 2022
35.96 M USD
Jan 1, 2023
46.78 M USD
Jan 1, 2024
7.54 M USD
Jan 1, 2025
7.58 M USD
The Arcellx Short-term Debt history
YEARShort-term DebtYoY
7.58 MUSD+0.56%
7.54 MUSD-83.89%
46.78 MUSD+30.10%
35.96 MUSD+35,861.00%
100,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Short-Term Debt of Arcellx is 7.58 M USD in 2025.

Short-Term Debt of Arcellx changed from 7.54 M USD to 7.58 M USD, representing a 0.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Arcellx since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Arcellx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Arcellx

All Key Metrics — Arcellx